Amendment to “Interim Guidelines on the Management and Administration of Pfizer COVID-19 Vaccine to Pediatric Population Ages 5-11 Years Old”

The amendment updates the Department Memo No. 2022-0041 dated 24 January 2022, entitled “Interim Guidelines on the Management and Administration of Tozinameran COVID-19 mRNA vaccine (nucleoside-modified) [Comirnaty] Pfizer COVID-19 Vaccine to Pediatric Population Ages 5-11 Years Old”. It seeks to avoid misinterpretation during implementation (English).